European Journal of Cancer
Volume 41, Issue 17 , Pages 2655-2661 , November 2005

Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: A single-centre experience

  • G.G. Steger

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18–20 währinger Gürtel, A-1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 140 400 5466; fax: +43 140 400 6081.
    • ,
  • R. Bartsch

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18–20 währinger Gürtel, A-1090 Vienna, Austria
    • ,
  • C. Wenzel

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18–20 währinger Gürtel, A-1090 Vienna, Austria
    • ,
  • U. Pluschnig

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18–20 währinger Gürtel, A-1090 Vienna, Austria
    • ,
  • D. Hussian

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18–20 währinger Gürtel, A-1090 Vienna, Austria
    • ,
  • U. Sevelda

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18–20 währinger Gürtel, A-1090 Vienna, Austria
    • ,
  • G.J. Locker

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18–20 währinger Gürtel, A-1090 Vienna, Austria
    • ,
  • M.F. Gnant

      Affiliations

    • Department of Surgery, Medical University of Vienna, Vienna, Austria
    • ,
  • R. Jakesz

      Affiliations

    • Department of Surgery, Medical University of Vienna, Vienna, Austria
    • ,
  • C.C. Zielinski

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 18–20 währinger Gürtel, A-1090 Vienna, Austria

Received 15 March 2005 ,Revised 1 July 2005 ,Accepted 7 July 2005.

References 

  1. Carlson RW, Anderson BO, Bensinger W, et al. NCCN Practice Guidelines for Breast Cancer. JNCCN. 2003;1:148–188
  2. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res. 1998;4:527–534
  3. Hortobagyi GN. Progress in endocrine therapy for breast carcinoma. Cancer. 1998;83:1–6
  4. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–3873
  5. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000;7:17–28
  6. Robertson JFR, Nicholson RI, Bundred NJ. Comparison of the short-term biological effects of fulvestrant with (ICI 182, 780) tamoxifen in postmenopausal women with primary breast cancer. Breast Cancer Res Treat. 2000;59:99
  7. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–3403
  8. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386–3395
  9. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women – a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229–238
  10. Pippen J, Osborne CK, Howell A, et al. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trials. Breast Cancer Res Treat. 2003;82(Suppl. 1):S101;(abstr 426)
  11. Reines A, Neumeister B, Spona J, et al. Immunocytochemical localization of estrogen and progesterone receptors and prognosis in human primary breast cancer. Cancer Res. 1990;50:7057–7061
  12. Perey L, Thürlimann B, Hawle H, et al. Fulvestrant (‘Faslodex’) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res Treat. 2002;76(Suppl. 1):S72;(abstr 249)
  13. Franco S, Perez A, Tan-Chiu E, et al. Fulvestrant (Faslodex(R)) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experience. Breast Cancer Res Treat. 2003;82(Suppl. 1):S105;(abstr 439)
  14. Petruzelka L, Zimovjanova M. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy – results from an expanded access programme. Eur J Cancer. 2004;2(Suppl.):132;(abstr 264)
  15. Vergote I, Robertson JFR, Kleeberg U, et al. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003;79:207–211
  16. Howell A. Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat. 2002;76(Suppl. 1):S72;(abstr 251)
  17. Robertson JFR, Howell A, Abram P, et al. Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann Oncol. 2002;13(Suppl. 5):46;(abstr 164O)
  18. Howell A, Robertson JFR, Abram P, et al. Comparison of fulvestrant v tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605–1613
  19. Nicholson RI, Gee JMW, Knowlden J, et al. The biology of antihormone failure in breast cancer. Breast Cancer Res Treat. 2003;80:29–34
  20. Pietras RJ, Marquez DC, Chen HW, et al. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat. 2003;82(Suppl. 1):S12;(abstr 22)
  21. Carlson RW, Henderson IC. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat. 2003;80:19–26

PII: S0959-8049(05)00725-2

doi: 10.1016/j.ejca.2005.07.016

European Journal of Cancer
Volume 41, Issue 17 , Pages 2655-2661 , November 2005

Article Tools

* Image Usage & Resolution